<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Cytotoxic chemotherapy for metastatic melanoma</title><link href="/z/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/z/d/css/icofont.min.css" rel="stylesheet"/><link href="/z/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/z/d/css/animate.css" rel="stylesheet"/><link href="/z/d/css/owl.carousel.css" rel="stylesheet"/><link href="/z/d/css/magnific-popup.css" rel="stylesheet"/><link href="/z/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/z/d/css/style.css" rel="stylesheet"/><link href="/z/d/css/rtl_edited.css" rel="stylesheet"/><link href="/z/d/css/responsive.css" rel="stylesheet"/><link href="https:///uptodate_assets/main.css" rel="stylesheet"/>
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>
<meta content="" name="description"/>
<link href="/z/d/img/favicon.png" rel="icon" type="image/png">
</link></head>
<body>
<!-- Start Main Menu Area -->
<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>
<section class="teacher-area ptb-10">
<div class="container">
</div>
<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Cytotoxic chemotherapy for metastatic melanoma</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Cytotoxic chemotherapy for metastatic melanoma</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Author:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Jeffrey A Sosman, MD</a></dd><dt><span> </span>Section Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Michael B Atkins, MD</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Melinda Yushak, MD, MPH</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> Apr 30, 2022.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H100464857"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span>Although the incidence of malignant melanoma is increasing, most cases are diagnosed at an early stage. Surgical excision is curative in most cases of early-stage disease, and patients at high risk of developing metastatic disease may benefit from adjuvant therapy with anti-programmed cell death receptor 1 (PD-1) inhibitors (eg, <a class="drug drug_general" data-topicid="96957" href="/z/d/drug information/96957.html" rel="external">pembrolizumab</a> or <a class="drug drug_general" data-topicid="98764" href="/z/d/drug information/98764.html" rel="external">nivolumab</a>) or MEK plus BRAF inhibitors (eg, <a class="drug drug_general" data-topicid="89686" href="/z/d/drug information/89686.html" rel="external">dabrafenib</a> plus <a class="drug drug_general" data-topicid="89685" href="/z/d/drug information/89685.html" rel="external">trametinib</a>) for <em>BRAF</em> V600 mutant melanoma. (See  <a class="medical medical_review" href="/z/d/html/7620.html" rel="external">"Surgical management of primary cutaneous melanoma or melanoma at other unusual sites"</a> and  <a class="medical medical_review" href="/z/d/html/7615.html" rel="external">"Adjuvant and neoadjuvant therapy for cutaneous melanoma"</a>.)</p><p>Most patients with stage IV disease require systemic treatment  (<a class="graphic graphic_table graphicRef110663 graphicRef110664" href="/z/d/graphic/110663.html" rel="external">table 1A-B</a>). For patients with extracranial metastatic melanoma, cytotoxic chemotherapy historically was widely used in patients who were not candidates for therapy with high-dose interleukin-2 (IL-2), although this approach was never demonstrated to improve survival. However, with the development of checkpoint inhibitor immunotherapy and targeted therapy for <em>BRAF</em>-mutated tumors, chemotherapy is now generally limited to second- or third-line settings and is frequently omitted altogether.</p><p>The clinical role of cytotoxic chemotherapy will be reviewed here. An overview of the management of advanced melanoma is presented separately.</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/85841.html" rel="external">"Overview of the management of advanced cutaneous melanoma"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/15863.html" rel="external">"Systemic treatment of metastatic melanoma lacking a BRAF mutation"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/15408.html" rel="external">"Systemic treatment of metastatic melanoma with BRAF and other molecular alterations"</a>.)</p><p></p><p class="headingAnchor" id="H274871397"><span class="h1">CHOICE OF THERAPY FOR DISSEMINATED DISEASE</span><span class="headingEndMark"> — </span>Approaches that have been shown to provide clinically important benefit for patients with disseminated melanoma in appropriately selected patients include immunotherapy with checkpoint inhibitors targeting cytotoxic T-lymphocyte-associated antigen 4 (CTLA-4) or programmed cell death receptor 1 (PD-1), and therapy targeting the mitogen-activated protein (MAP) kinase pathway with a combination of BRAF and MEK inhibitors in patients whose tumors contain a V600 mutation in the <em>BRAF </em>gene.</p><p>Cytotoxic chemotherapy does not have an established role in the management of patients with advanced melanoma. However, chemotherapy retains a role as therapy for patients whose disease can no longer be controlled with immunotherapy or targeted agents and who are not eligible or able to enroll in a clinical trial. Although chemotherapy has not been demonstrated to increase overall survival, combination regimens and single-agent chemotherapy have been associated with objective responses in a minority of patients. (See <a class="local">'Combination regimens'</a> below and <a class="local">'Single-agent chemotherapy'</a> below.)</p><p>The factors influencing the choice of therapy are discussed separately. (See  <a class="medical medical_review" href="/z/d/html/85841.html" rel="external">"Overview of the management of advanced cutaneous melanoma"</a>.)</p><p class="headingAnchor" id="H100464864"><span class="h1">SINGLE-AGENT CHEMOTHERAPY</span><span class="headingEndMark"> — </span>The most widely used chemotherapy agents for the treatment of advanced melanoma are <a class="drug drug_general" data-topicid="9316" href="/z/d/drug information/9316.html" rel="external">dacarbazine</a> and its prodrug <a class="drug drug_general" data-topicid="9699" href="/z/d/drug information/9699.html" rel="external">temozolomide</a>. Other agents that may have demonstrated at least some activity include nitrosoureas, platinum compounds, vinca alkaloids, and taxanes.</p><p class="headingAnchor" id="H100464871"><span class="h2">Dacarbazine and temozolomide</span></p><p class="headingAnchor" id="H100464879"><span class="h3">Dacarbazine</span><span class="headingEndMark"> — </span><a class="drug drug_general" data-topicid="9316" href="/z/d/drug information/9316.html" rel="external">Dacarbazine</a> has been widely used for the treatment of patients with metastatic melanoma. Although there are no phase III trials that have demonstrated a survival benefit for dacarbazine compared with a "no treatment" control, it is approved for this indication in the United States. Dacarbazine is generally considered to be the most active single agent in patients with metastatic melanoma, with a response rate of 8 to 20 percent. The vast majority of responses are only partial, and the median response duration is four to six months [<a href="#rid1">1,2</a>]. Long-term follow-up of patients treated with dacarbazine indicates that less than 2 percent of patients can be anticipated to survive six years [<a href="#rid3">3</a>].</p><p><a class="drug drug_general" data-topicid="9316" href="/z/d/drug information/9316.html" rel="external">Dacarbazine</a> is generally well tolerated, with the major side effect being nausea and vomiting. Dacarbazine administration requires good venous access because of the potential for chemical phlebitis. Bone marrow suppression is usually only modest, and alopecia and fatigue are minimal, allowing most patients to maintain relatively normal function while receiving therapy.</p><p>Typical schedules for <a class="drug drug_general" data-topicid="9316" href="/z/d/drug information/9316.html" rel="external">dacarbazine</a> are 200 mg/m<sup>2</sup> intravenously for five days or 850 to 1000 mg/m<sup>2</sup> intravenously over one hour every two to four weeks. Response rates and response duration do not appear to be affected by the administration schedule. The availability of powerful antiemetic agents permits the more convenient, one day every three to four weeks schedule to be administered in an outpatient setting. (See  <a class="medical medical_review" href="/z/d/html/1151.html" rel="external">"Prevention of chemotherapy-induced nausea and vomiting in adults"</a>.)</p><p>Clinical trials have consistently demonstrated a significant overall survival advantage for targeted therapies or checkpoint inhibitor immunotherapy over <a class="drug drug_general" data-topicid="9316" href="/z/d/drug information/9316.html" rel="external">dacarbazine</a>. (See  <a class="medical medical_review" href="/z/d/html/15408.html" rel="external">"Systemic treatment of metastatic melanoma with BRAF and other molecular alterations", section on 'BRAF V600 mutant disease'</a>.)</p><p class="headingAnchor" id="H100464886"><span class="h3">Temozolomide</span><span class="headingEndMark"> — </span><a class="drug drug_general" data-topicid="9699" href="/z/d/drug information/9699.html" rel="external">Temozolomide</a> is an analog of <a class="drug drug_general" data-topicid="9316" href="/z/d/drug information/9316.html" rel="external">dacarbazine</a> that is chemically degraded at physiologic pH to MTIC, the active metabolite of dacarbazine [<a href="#rid4">4</a>]. In contrast to dacarbazine, temozolomide does not require metabolic activation. Unlike dacarbazine, temozolomide is orally absorbed; it can cross the blood brain barrier and may have some activity in brain metastases. (See  <a class="medical medical_review" href="/z/d/html/7611.html" rel="external">"Management of brain metastases in melanoma"</a>.)</p><p><a class="drug drug_general" data-topicid="9699" href="/z/d/drug information/9699.html" rel="external">Temozolomide</a> has been compared with <a class="drug drug_general" data-topicid="9316" href="/z/d/drug information/9316.html" rel="external">dacarbazine</a> in two randomized trials. In a phase III trial that included 305 patients with metastatic melanoma, treatment with temozolomide was associated with nonsignificant improvements in overall survival and progression-free survival compared with dacarbazine (median 7.7 versus 6.4 and 1.9 versus 1.5 months, respectively) [<a href="#rid5">5</a>]. Similarly, in a trial conducted by the European Organisation for Research and Treatment of Cancer (EORTC) in 859 patients with metastatic melanoma, there was no difference in overall or progression-free survival (median 9.1 versus 9.4 and 2.3 versus 2.2 months, respectively) [<a href="#rid6">6</a>].</p><p>Experimental approaches to augment the activity of <a class="drug drug_general" data-topicid="9699" href="/z/d/drug information/9699.html" rel="external">temozolomide</a> have not been successful, and the clinical data have not been sufficiently compelling to achieve US Food and Drug Administration (FDA) approval for the treatment of metastatic melanoma.</p><p class="headingAnchor" id="H100474841"><span class="h2">Fotemustine</span><span class="headingEndMark"> — </span>The nitrosoureas fotemustine, <a class="drug drug_general" data-topicid="9206" href="/z/d/drug information/9206.html" rel="external">carmustine</a> (BCNU), and <a class="drug drug_general" data-topicid="9569" href="/z/d/drug information/9569.html" rel="external">lomustine</a> (CCNU) all have produced overall response rates of 13 to 18 percent in patients with metastatic melanoma [<a href="#rid1">1,2,7</a>]. Alopecia is more severe with these agents than with <a class="drug drug_general" data-topicid="9316" href="/z/d/drug information/9316.html" rel="external">dacarbazine</a>, and hematologic toxicity, particularly thrombocytopenia, is more prolonged.</p><p>In a phase III trial, 229 patients with advanced disease with or without brain metastases were randomly assigned to fotemustine or <a class="drug drug_general" data-topicid="9316" href="/z/d/drug information/9316.html" rel="external">dacarbazine</a> [<a href="#rid7">7</a>]. The objective response rate was twice as high with fotemustine compared with dacarbazine (15 versus 7 percent), but the median time to progression (1.9 and 1.8 months, respectively) and median survival (7.3 and 5.6 months, respectively) were not significantly different. Among patients without brain metastases, those randomly assigned to fotemustine had a lower risk of cerebral progression (18 versus 23 percent) and a significantly longer time to the development of brain metastases (22.7 versus 7.2 months) compared with those assigned to dacarbazine. This finding requires independent confirmation.</p><p>Although there were some initially encouraging results when <a class="drug drug_general" data-topicid="9569" href="/z/d/drug information/9569.html" rel="external">lomustine</a> was administered via the hepatic artery, a randomized trial failed to demonstrate any improvement in survival when compared with intravenous administration [<a href="#rid8">8</a>]. (See  <a class="medical medical_review" href="/z/d/html/113047.html" rel="external">"Metastatic uveal melanoma", section on 'Locoregional therapies'</a>.)</p><p>Although fotemustine is considered first-line chemotherapy in some European countries, it is not available in the United States.</p><p class="headingAnchor" id="H100464901"><span class="h2">Platinum compounds</span><span class="headingEndMark"> — </span><a class="drug drug_general" data-topicid="9271" href="/z/d/drug information/9271.html" rel="external">Cisplatin</a> and <a class="drug drug_general" data-topicid="9202" href="/z/d/drug information/9202.html" rel="external">carboplatin</a> have shown only modest activity in patients with metastatic melanoma. Single-agent cisplatin has been tested at doses up to 200 mg/m<sup>2</sup>, with response rates ranging from 0 to 53 percent (mean 15 to 20 percent) [<a href="#rid1">1</a>]. Single-arm studies have provided evidence for some dose dependency. In one study, for example, single-agent cisplatin was given at doses up to 150 mg/m<sup>2</sup> in combination with <a class="drug drug_general" data-topicid="8533" href="/z/d/drug information/8533.html" rel="external">amifostine</a>, a thiol derivative with protective effects on bone marrow and renal tissue. Tumor responses were noted in 53 percent of patients, but all were partial and the median response duration was only four months [<a href="#rid9">9</a>].</p><p><a class="drug drug_general" data-topicid="9202" href="/z/d/drug information/9202.html" rel="external">Carboplatin</a> has been less extensively tested [<a href="#rid10">10</a>], and its activity compared with other single agents is uncertain. It has been primarily tested in combination with <a class="drug drug_general" data-topicid="9735" href="/z/d/drug information/9735.html" rel="external">paclitaxel</a>. Platinum compounds have also been extensively studied in biochemotherapy combinations.</p><p class="headingAnchor" id="H1663873008"><span class="h2">Nanoparticle albumin-bound paclitaxel</span><span class="headingEndMark"> — </span>Nanoparticle albumin-bound <a class="drug drug_general" data-topicid="9735" href="/z/d/drug information/9735.html" rel="external">paclitaxel</a> (<a class="drug drug_general" data-topicid="10159" href="/z/d/drug information/10159.html" rel="external">nabpaclitaxel</a>) showed evidence of activity in a phase II clinical study, with response rates of 22 and 3 percent in chemotherapy-naïve and previously treated patients [<a href="#rid11">11</a>].</p><p>Based upon this, a phase III trial was conducted in which 529 previously untreated patients with metastatic melanoma were randomly assigned to <a class="drug drug_general" data-topicid="10159" href="/z/d/drug information/10159.html" rel="external">nabpaclitaxel</a> or <a class="drug drug_general" data-topicid="9316" href="/z/d/drug information/9316.html" rel="external">dacarbazine</a> [<a href="#rid12">12</a>]. Progression-free survival, the primary endpoint, was significantly increased with nabpaclitaxel (median 4.8 versus 2.5 months, hazard ratio [HR] 0.79, 95% CI 0.63-0.99). The difference in overall survival was not statistically significant between nabpaclitaxel and dacarbazine (median 12.6 versus 10.5 months, HR 0.9, 95% CI 0.74-1.09, p = 0.27]), and the difference in objective response rate on independent review was not statistically significant (15 versus 11 percent). Subsequent analyses indicated that nabpaclitaxel had similar activity in those with wild-type <em>BRAF</em> and those with mutated <em>BRAF</em> [<a href="#rid13">13</a>].</p><p class="headingAnchor" id="H100464915"><span class="h2">Other agents</span><span class="headingEndMark"> — </span>Microtubule toxins, such as vinca alkaloids [<a href="#rid14">14</a>], and agents that interfere with microtubule disassembly, such as taxanes [<a href="#rid15">15-17</a>], have shown only modest activity in patients with metastatic melanoma. These agents have been studied primarily in combinations.</p><p class="headingAnchor" id="H100464922"><span class="h1">COMBINATION REGIMENS</span><span class="headingEndMark"> — </span>There are no randomized trials that have established the superiority of combination chemotherapy or biochemotherapy regimens compared with single-agent <a class="drug drug_general" data-topicid="9316" href="/z/d/drug information/9316.html" rel="external">dacarbazine</a> or <a class="drug drug_general" data-topicid="9699" href="/z/d/drug information/9699.html" rel="external">temozolomide</a> in patients with metastatic melanoma. However, combination regimens may have a role in patients whose disease can no longer be controlled with immunotherapy and/or targeted therapy.</p><p class="headingAnchor" id="H466627844"><span class="h2">Dacarbazine or temozolomide combinations</span><span class="headingEndMark"> — </span>Phase III trials have not confirmed a survival advantage for various dacarbazine-based or temozolomide-based combinations compared with single-agents. </p><p>The lack of improvement in survival is illustrated by results from a multicenter trial in which 240 patients were randomly assigned to either <a class="drug drug_general" data-topicid="9316" href="/z/d/drug information/9316.html" rel="external">dacarbazine</a> or a combination of <a class="drug drug_general" data-topicid="9271" href="/z/d/drug information/9271.html" rel="external">cisplatin</a>, dacarbazine, <a class="drug drug_general" data-topicid="9206" href="/z/d/drug information/9206.html" rel="external">carmustine</a>, and <a class="drug drug_general" data-topicid="9972" href="/z/d/drug information/9972.html" rel="external">tamoxifen</a> (CDBT) [<a href="#rid18">18</a>]. Although the response rate with CDBT was marginally improved (19 versus 10 percent compared with dacarbazine alone, p = 0.09), median survival was seven months on both treatment arms. Toxicity (myelosuppression, nausea, vomiting, fatigue) was more severe with the combination regimen.</p><p class="headingAnchor" id="H466627851"><span class="h2">Carboplatin paclitaxel</span><span class="headingEndMark"> — </span>The combination of <a class="drug drug_general" data-topicid="9202" href="/z/d/drug information/9202.html" rel="external">carboplatin</a> and <a class="drug drug_general" data-topicid="9735" href="/z/d/drug information/9735.html" rel="external">paclitaxel</a> has not been directly compared with single-agent <a class="drug drug_general" data-topicid="9316" href="/z/d/drug information/9316.html" rel="external">dacarbazine</a> or <a class="drug drug_general" data-topicid="9699" href="/z/d/drug information/9699.html" rel="external">temozolomide</a>, but this regimen has activity and may be useful as second- or third-line therapy [<a href="#rid19">19,20</a>]. The most extensive data come from a phase III trial in which carboplatin paclitaxel was compared with carboplatin paclitaxel plus <a class="drug drug_general" data-topicid="10277" href="/z/d/drug information/10277.html" rel="external">sorafenib</a> as first-line therapy in 823 patients with metastatic melanoma [<a href="#rid19">19</a>]. Although the addition of sorafenib did not improve outcomes, the objective response rate for the entire cohort was 18 to 20 percent, and the median overall survival was 11 months on both treatment arms.</p><p class="headingAnchor" id="H466627858"><span class="h2">Carboplatin paclitaxel bevacizumab</span><span class="headingEndMark"> — </span>The addition of <a class="drug drug_general" data-topicid="8683" href="/z/d/drug information/8683.html" rel="external">bevacizumab</a> to <a class="drug drug_general" data-topicid="9202" href="/z/d/drug information/9202.html" rel="external">carboplatin</a> <a class="drug drug_general" data-topicid="9735" href="/z/d/drug information/9735.html" rel="external">paclitaxel</a> may improve disease control compared with carboplatin paclitaxel alone. In the phase II BEAM trial, the combination of carboplatin paclitaxel and bevacizumab was compared with carboplatin paclitaxel alone in 214 patients with metastatic melanoma [<a href="#rid21">21</a>]. In the entire study population, there was a trend toward improved overall survival (median 12.3 versus 8.6 months, hazard ratio [HR] 0.67, 95% CI 0.46-0.98), although this benefit was not statistically significant with longer follow-up  (<a class="graphic graphic_table graphicRef110663" href="/z/d/graphic/110663.html" rel="external">table 1A</a>).</p><p class="headingAnchor" id="H3755212051"><span class="h1">SOCIETY GUIDELINE LINKS</span><span class="headingEndMark"> — </span>Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See  <a class="medical medical_society_guidelines" href="/z/d/html/118501.html" rel="external">"Society guideline links: Melanoma screening, prevention, diagnosis, and management"</a>.)</p><p class="headingAnchor" id="H100475877"><span class="h1">INFORMATION FOR PATIENTS</span><span class="headingEndMark"> — </span>UpToDate offers two types of patient education materials, "The Basics" and "Beyond the Basics." The Basics patient education pieces are written in plain language, at the 5<sup>th</sup> to 6<sup>th</sup> grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10<sup>th</sup> to 12<sup>th</sup> grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.</p><p>Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on "patient info" and the keyword(s) of interest.)</p><p class="bulletIndent1"><span class="glyph">●</span>Beyond the Basics topics (see  <a class="medical medical_patient" href="/z/d/html/889.html" rel="external">"Patient education: Melanoma treatment; localized melanoma (Beyond the Basics)"</a> and  <a class="medical medical_patient" href="/z/d/html/892.html" rel="external">"Patient education: Melanoma treatment; advanced or metastatic melanoma (Beyond the Basics)"</a>)</p><p></p><p class="headingAnchor" id="H100475599"><span class="h1">SUMMARY AND RECOMMENDATIONS</span></p><p class="bulletIndent1"><span class="glyph">●</span>Checkpoint immunotherapy targeting programmed cell death receptor 1 (PD-1) and/or cytotoxic T-lymphocyte-associated antigen 4 (CTLA-4), and therapy targeting the mitogen-activated protein (MAP) kinase pathway with BRAF and MEK inhibitors are preferred modalities for the initial systemic treatment of patients with advanced melanoma. (See  <a class="medical medical_review" href="/z/d/html/85841.html" rel="external">"Overview of the management of advanced cutaneous melanoma"</a> and  <a class="medical medical_review" href="/z/d/html/15863.html" rel="external">"Systemic treatment of metastatic melanoma lacking a BRAF mutation"</a> and  <a class="medical medical_review" href="/z/d/html/15408.html" rel="external">"Systemic treatment of metastatic melanoma with BRAF and other molecular alterations"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>For patients who are not candidates for further immunotherapy or targeted therapy, who are not candidates for inclusion in a formal clinical trial, and who are interested in additional therapy, chemotherapy may be an option. These approaches have not been proven to increase overall survival, but they are associated with objective responses in a minority of patients.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>In these patients, we suggest a combination of <a class="drug drug_general" data-topicid="9202" href="/z/d/drug information/9202.html" rel="external">carboplatin</a> and <a class="drug drug_general" data-topicid="9735" href="/z/d/drug information/9735.html" rel="external">paclitaxel</a> (<a class="grade" href="https:///uptodate/show/grade_6" rel="external">Grade 2C</a>). (See <a class="local">'Carboplatin paclitaxel'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Single-agent chemotherapy (<a class="drug drug_general" data-topicid="9316" href="/z/d/drug information/9316.html" rel="external">dacarbazine</a>, <a class="drug drug_general" data-topicid="9699" href="/z/d/drug information/9699.html" rel="external">temozolomide</a>, fotemustine, nanoparticle albumin-bound <a class="drug drug_general" data-topicid="9735" href="/z/d/drug information/9735.html" rel="external">paclitaxel</a> [<a class="drug drug_general" data-topicid="10159" href="/z/d/drug information/10159.html" rel="external">nabpaclitaxel</a>]) is an appropriate alternative. (See <a class="local">'Single-agent chemotherapy'</a> above.)</p></div><div class="headingAnchor" id="references"><ol id="reference"><li class="breakAll">Atkins MB. The role of cytotoxic chemotherapeutic agents either alone or in combination with biological response modifiers. In: Molecular Diagnosis, Prevention &amp; Therapy of Melanoma, Kirkwood JK (Ed), Marcel Dekker, New York 1997. p.219.</li><li class="breakAll">Houghton AN, Legha S, Bajorin DF. Chemotherapy for metastatic melanoma. In: Cutaneous Melanoma, 2nd, Balch, Houghton, Milton, et al (Eds), JB Lippincott Company, Philadelphia  p.498.</li><li><a class="nounderline abstract_t">Hill GJ 2nd, Krementz ET, Hill HZ. Dimethyl triazeno imidazole carboxamide and combination therapy for melanoma. IV. Late results after complete response to chemotherapy (Central Oncology Group protocols 7130, 7131, and 7131A). Cancer 1984; 53:1299.</a></li><li><a class="nounderline abstract_t">Stevens MF, Hickman JA, Langdon SP, et al. Antitumor activity and pharmacokinetics in mice of 8-carbamoyl-3-methyl-imidazo[5,1-d]-1,2,3,5-tetrazin-4(3H)-one (CCRG 81045; M &amp; B 39831), a novel drug with potential as an alternative to dacarbazine. Cancer Res 1987; 47:5846.</a></li><li><a class="nounderline abstract_t">Middleton MR, Grob JJ, Aaronson N, et al. Randomized phase III study of temozolomide versus dacarbazine in the treatment of patients with advanced metastatic malignant melanoma. J Clin Oncol 2000; 18:158.</a></li><li><a class="nounderline abstract_t">Patel PM, Suciu S, Mortier L, et al. Extended schedule, escalated dose temozolomide versus dacarbazine in stage IV melanoma: final results of a randomised phase III study (EORTC 18032). Eur J Cancer 2011; 47:1476.</a></li><li><a class="nounderline abstract_t">Avril MF, Aamdal S, Grob JJ, et al. Fotemustine compared with dacarbazine in patients with disseminated malignant melanoma: a phase III study. J Clin Oncol 2004; 22:1118.</a></li><li><a class="nounderline abstract_t">Leyvraz S, Piperno-Neumann S, Suciu S, et al. Hepatic intra-arterial versus intravenous fotemustine in patients with liver metastases from uveal melanoma (EORTC 18021): a multicentric randomized trial. Ann Oncol 2014; 25:742.</a></li><li><a class="nounderline abstract_t">Glover D, Glick JH, Weiler C, et al. WR-2721 and high-dose cisplatin: an active combination in the treatment of metastatic melanoma. J Clin Oncol 1987; 5:574.</a></li><li><a class="nounderline abstract_t">Evans LM, Casper ES, Rosenbluth R. Phase II trial of carboplatin in advanced malignant melanoma. Cancer Treat Rep 1987; 71:171.</a></li><li><a class="nounderline abstract_t">Hersh EM, O'Day SJ, Ribas A, et al. A phase 2 clinical trial of nab-paclitaxel in previously treated and chemotherapy-naive patients with metastatic melanoma. Cancer 2010; 116:155.</a></li><li><a class="nounderline abstract_t">Hersh EM, Del Vecchio M, Brown MP, et al. A randomized, controlled phase III trial of nab-Paclitaxel versus dacarbazine in chemotherapy-naïve patients with metastatic melanoma. Ann Oncol 2015; 26:2267.</a></li><li class="breakAll">Hersh E, et al. A phase III trial of nab-paclitaxel versus dacarbazine in chemotherapy-naive patients with metastatic melanoma: A subanalysis based on BRAF status (abstract 9030). American Society of Clinical Oncology 2013 meeting.</li><li><a class="nounderline abstract_t">Quagliana JM, Stephens RL, Baker LH, Costanzi JJ. Vindesine in patients with metastatic malignant melanoma: a Southwest Oncology Group study. J Clin Oncol 1984; 2:316.</a></li><li><a class="nounderline abstract_t">Aamdal S, Wolff I, Kaplan S, et al. Docetaxel (Taxotere) in advanced malignant melanoma: a phase II study of the EORTC Early Clinical Trials Group. Eur J Cancer 1994; 30A:1061.</a></li><li><a class="nounderline abstract_t">Bedikian AY, DeConti RC, Conry R, et al. Phase 3 study of docosahexaenoic acid-paclitaxel versus dacarbazine in patients with metastatic malignant melanoma. Ann Oncol 2011; 22:787.</a></li><li><a class="nounderline abstract_t">Goldinger SM, Buder-Bakhaya K, Lo SN, et al. Chemotherapy after immune checkpoint inhibitor failure in metastatic melanoma: a retrospective multicentre analysis. Eur J Cancer 2022; 162:22.</a></li><li><a class="nounderline abstract_t">Chapman PB, Einhorn LH, Meyers ML, et al. Phase III multicenter randomized trial of the Dartmouth regimen versus dacarbazine in patients with metastatic melanoma. J Clin Oncol 1999; 17:2745.</a></li><li><a class="nounderline abstract_t">Flaherty KT, Lee SJ, Zhao F, et al. Phase III trial of carboplatin and paclitaxel with or without sorafenib in metastatic melanoma. J Clin Oncol 2013; 31:373.</a></li><li><a class="nounderline abstract_t">Hauschild A, Agarwala SS, Trefzer U, et al. Results of a phase III, randomized, placebo-controlled study of sorafenib in combination with carboplatin and paclitaxel as second-line treatment in patients with unresectable stage III or stage IV melanoma. J Clin Oncol 2009; 27:2823.</a></li><li><a class="nounderline abstract_t">Kim KB, Sosman JA, Fruehauf JP, et al. BEAM: a randomized phase II study evaluating the activity of bevacizumab in combination with carboplatin plus paclitaxel in patients with previously untreated advanced melanoma. J Clin Oncol 2012; 30:34.</a></li></ol></div><div id="topicVersionRevision">Topic 15406 Version 46.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="javascript:alert('بدون لینک');" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : Atkins MB. The role of cytotoxic chemotherapeutic agents either alone or in combination with biological response modifiers. In: Molecular Diagnosis, Prevention &amp; Therapy of Melanoma, Kirkwood JK (Ed), Marcel Dekker, New York 1997. p.219.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="javascript:alert('بدون لینک');" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : Houghton AN, Legha S, Bajorin DF. Chemotherapy for metastatic melanoma. In: Cutaneous Melanoma, 2nd, Balch, Houghton, Milton, et al (Eds), JB Lippincott Company, Philadelphia  p.498.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6362841" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : Dimethyl triazeno imidazole carboxamide and combination therapy for melanoma. IV. Late results after complete response to chemotherapy (Central Oncology Group protocols 7130, 7131, and 7131A).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3664486" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : Antitumor activity and pharmacokinetics in mice of 8-carbamoyl-3-methyl-imidazo[5,1-d]-1,2,3,5-tetrazin-4(3H)-one (CCRG 81045; M&amp;B 39831), a novel drug with potential as an alternative to dacarbazine.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10623706" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : Randomized phase III study of temozolomide versus dacarbazine in the treatment of patients with advanced metastatic malignant melanoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21600759" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : Extended schedule, escalated dose temozolomide versus dacarbazine in stage IV melanoma: final results of a randomised phase III study (EORTC 18032).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15020614" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : Fotemustine compared with dacarbazine in patients with disseminated malignant melanoma: a phase III study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24510314" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : Hepatic intra-arterial versus intravenous fotemustine in patients with liver metastases from uveal melanoma (EORTC 18021): a multicentric randomized trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3031224" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : WR-2721 and high-dose cisplatin: an active combination in the treatment of metastatic melanoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3542209" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : Phase II trial of carboplatin in advanced malignant melanoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19877111" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : A phase 2 clinical trial of nab-paclitaxel in previously treated and chemotherapy-naive patients with metastatic melanoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26410620" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : A randomized, controlled phase III trial of nab-Paclitaxel versus dacarbazine in chemotherapy-naïve patients with metastatic melanoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26410620" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : A randomized, controlled phase III trial of nab-Paclitaxel versus dacarbazine in chemotherapy-naïve patients with metastatic melanoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6707719" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : Vindesine in patients with metastatic malignant melanoma: a Southwest Oncology Group study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7654429" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : Docetaxel (Taxotere) in advanced malignant melanoma: a phase II study of the EORTC Early Clinical Trials Group.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20855467" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : Phase 3 study of docosahexaenoic acid-paclitaxel versus dacarbazine in patients with metastatic malignant melanoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34952480" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : Chemotherapy after immune checkpoint inhibitor failure in metastatic melanoma: a retrospective multicentre analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10561349" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : Phase III multicenter randomized trial of the Dartmouth regimen versus dacarbazine in patients with metastatic melanoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23248256" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : Phase III trial of carboplatin and paclitaxel with or without sorafenib in metastatic melanoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19349552" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : Results of a phase III, randomized, placebo-controlled study of sorafenib in combination with carboplatin and paclitaxel as second-line treatment in patients with unresectable stage III or stage IV melanoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22124101" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : BEAM: a randomized phase II study evaluating the activity of bevacizumab in combination with carboplatin plus paclitaxel in patients with previously untreated advanced melanoma.</p>
</a>
</div>
</div>
</div>
</div>
</section>
</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->
<!-- End Footer Area -->
<!-- Back to top -->
<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->
<!-- Prpper JS -->
<!-- Bootstrap Min JS -->
<!-- Classy Nav Min Js -->
<!-- Owl Carousel Min Js -->
<!-- Magnific Popup JS -->
<!-- CounterUp JS -->
<!-- Waypoints JS -->
<!-- Form Validator Min JS -->
<!-- Contact Form Min JS -->
<!-- Main JS -->
<!-- Global site tag (gtag.js) - Google Analytics -->
</body>
</html>
